The Gulf Time Newspaper One of the finest business newspapers in the UAE brought to you by our professional writers and editors.
Abu Dhabi /Â WAM
Julphar Gulf Pharmaceutical Industries expressed its intention to develop and expand in more than 34 countries around the world, consolidating its prominent position in the global pharmaceutical industry.
Emirates News Agency (WAM) met with Dr Hosam Badr, Marketing Director at Julphar, on the sidelines of the Global Manufacturing & Industrialisation Summit (GMIS), where he spoke about the company’s goal through its participation in the summit held from March 28-30, under the patronage of His Highness Sheikh Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces.
Badr stressed that Julphar had participated in this summit to discuss the pharmaceutical industry and its future projects. The company plans to expand and enter new markets, he revealed, pointing to the Julphar factory in Saudi Arabia which will be opened soon, as well as the factories in Bangladesh and Ethiopia, in addition to projects in Morocco, Algeria and Egypt, where medicines are being manufactured locally.
The company’s expansion plans include 34 countries around the world, and it plans to export more than 90 percent of its products he added. Julphar is considered among the leading companies that exports to countries such Saudi Arabia, which is the biggest market for the company in the region, as well as Kuwait, Omar, Yemen, Iraq and Lebanon, he remarked.
He emphasised the company is now focussing on the development of the insulin project. The company established a factory to manufacture raw insulin, a major achievement because there are few factories around the world that have obtained the technology required for the production of insulin, he mentioned.
The company has established this factory upon the directives of Sheikh Faisal bin Saqr Al Qasimi, Chairman of Julphar Gulf Pharmaceutical Industries, he said, stressing that the company had started producing insulin locally and developing normal insulin to become more sophisticated.
He highlighted the alternative medicine project being carried out by the company, including components similar to the natural materials produced in the human body, which are being developed and enhanced to guarantee the best medicines to the patients.
The company is exporting medicines to the Latin America countries, New Zealand and the United States, he added.